A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171 , a Novel Phosphodiesterase Type 5 Inhibitor
CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)
DOI: 10.1002/psp4.70298 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 18.07.2026. Verfasst von Guanghui Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vigonvita Life Sciences co., Ltd., Suzhou, China. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A Inhibitors, Models, Biological, Cytochrome P-450 CYP3A Inducers, Phosphodiesterase 5 Inhibitors. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
TPN171 is a potent phosphodiesterase type 5 inhibitor used to treat pulmonary arterial hypertension and erectile dysfunction, primarily metabolized by CYP3A4. This study aimed to evaluate its drug–drug interaction (DDI) potential and determine the optimal dosing when co‐administered with CYP3A4 modulators. A physiologically based pharmacokinetic (PBPK) model was developed and validated using clinical DDI data for itraconazole (strong CYP3A4 inhibitor) and rifampin (strong CYP3A4 inducer). The model was then applied to predict DDIs with moderate (diltiazem, fluconazole) and mild (fluvoxamine) inhibitors, as well as moderate (efavirenz) and mild (zanubrutinib) inducers. Predicted AUC 0−t ratios aligned with observed data: itraconazole (2.42‐fold predicted vs. 2.67‐ fold observed) and rifampicin (0.14‐fold predicted vs. 0.096‐fold observed). For other modulators, geometric mean AUC 0−t ratios were 2.40 with diltiazem, 3.27 with fluconazole (400 mg), 2.07 with fluconazole (100 mg), 1.16 with fluvoxamine, 0.53 with efavirenz, and 0.70 with zanubrutinib. These simulations indicate that strong and moderate CYP3A4 inhibitors and inducers significantly alter TPN171 exposure, whereas weak modulators have no clinically meaningful impact. These findings provide a scientific basis for dose recommendations when TPN171 is used with CYP3A4 modulators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vigonvita Life Sciences co., Ltd., Suzhou, China.
- Shanghai PharmoGo co., Ltd, Shanghai, China.
- Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Fudan University, Shanghai, China.
ORCID-Profile: Guanghui Tian, Jiaxiang Juan, Jianghong Pei, Jingying Jia
Zitieren
APA
Tian, G., Chen, T., Li, L., Wang, Z., Yang, H., Juan, J., Duan, Y., Pei, J., & Jia, J. (2026). A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171 , a Novel Phosphodiesterase Type 5 Inhibitor. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70298
Vancouver
Tian G, Chen T, Li L, Wang Z, Yang H, Juan J, et al. A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171 , a Novel Phosphodiesterase Type 5 Inhibitor. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70298
BibTeX
@article{Tian2026,
author = {Tian, Guanghui and Chen, Tao and Li, Lei and Wang, Zhiqiang and Yang, Hao and Juan, Jiaxiang and Duan, Yuanqin and Pei, Jianghong and Jia, Jingying},
title = {A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171 , a Novel Phosphodiesterase Type 5 Inhibitor},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {8},
doi = {10.1002/psp4.70298}
}
EUVIMED